This trial is evaluating whether ToolboxDetect will improve 1 primary outcome and 4 secondary outcomes in patients with Cognitive Decline. Measurement will happen over the course of Up to 3 years.
This trial requires 41500 total participants across 2 different treatment groups
This trial involves 2 different treatments. ToolboxDetect is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Toolboxdetect is an effective and widely available cognitive screening tool in the aging population. Its high sensitivity to cognitive impairments in the aging population makes it a candidate for evaluating the impact of aging-related cognitive symptoms on clinical outcomes, including fall risk and functional decline." - Anonymous Online Contributor
"There is a wide range of features in the general population of the elderly associated with neuropathological change. There is a strong need for well-designed, prospective studies into the diagnosis of specific brain aging syndromes and for effective dementia preventive strategies." - Anonymous Online Contributor
"Mild cognitive decline is common among older adults and is associated with poorer function. Results from a recent clinical trial suggest that even mildly affected cognitive function should be evaluated in older patients to identify those who may require early intervention to avoid future decline." - Anonymous Online Contributor
"The numbers of people who experience cognitive decline in the real world are much larger. It is more than double the numbers reported in academic literature. The reasons for the discrepancy are uncertain but it highlights the fact that there is a lack of studies on cognitive decline in the real world which can be very informative." - Anonymous Online Contributor
"The most common types of post-mature cognitive decline were memory, attention, and executive functions. These impairments are related to the cognitive symptoms of older adults." - Anonymous Online Contributor
"The causes of cognitive decline are complex. They include the cognitive reserve (brain's ability) in which each person differs; the environment (exposure to risk factors for cognitive decline); and the individual's own age, genetics, and history. It is not possible to identify a single cause, such as a single germ. Understanding the complexity of causation is important for developing effective prevention measures." - Anonymous Online Contributor
"There is no single treatment for CAD or ND that can work in every patient. Instead, treatments which are effective in one domain such as memory might not work well in another domain such as thinking in a patient with CAD. There are no clinical trials designed specifically to test a particular treatment for CAD or ND. The majority of treatments for CAD and ND only try general strategies such as addressing the patient's environment and lifestyle and using the treatment they use for other conditions such as depression. These treatments have not been empirically tested for their long-term effectiveness in CAD or ND - so they cannot be recommended on their own and further observational studies are needed to confirm their effectiveness." - Anonymous Online Contributor
"Older people generally are better at holding and remembering information than are younger people. As people age, it becomes progressively more difficult to use and control information. In the case of simple information like the age of someone, in a given time frame, the memory may not degrade at a similar rate as the aging of the person. In many cognitive domains, there is a significant effect of age beginning in the mid-70s; by the late 80s, most people cannot hold or recall most information. It is important for caregivers to stay vigilant for cognitive decline, and to continue to keep a record of personal and family histories, as well as other important information." - Anonymous Online Contributor
"A toolboxdetect scan combined with either TBI or OA may be useful to identify AD. The presence of TBI, especially in conjunction with OA, in elderly people is important for early diagnosis and is independent of cognitive deterioration or dementia." - Anonymous Online Contributor
"The study findings do not support an increase in Alzheimer's disease (AD) risk with cumulative exposure to lead in adulthood. The current study findings showed a decrease of a composite measure of AD, which included the clinical diagnoses of AD or mild cognitive impairment (MCI). When analyzed by type of exposure (poetry, music, or lead), there was an interaction effect between cumulative exposure exposure and the measure of AD. For the measure of MCI the results showed some evidence of a decreasing effect of cumulative exposure. As the study analyzed cumulative exposure (poetry, music, or lead), there was an interaction effect between cumulative exposure exposure and the measure of MCI." - Anonymous Online Contributor
"Cognitive decline is common among older people and is associated with reduced quality of life and greater functional disability, and with high-risk of death at all ages. Cognitive deficits may affect our ability to engage in social and physical health-promoting activities." - Anonymous Online Contributor
"It seems that newer tools are bringing more information about patient needs and optimizing patient selection for treatment. This information adds to the clinician's ability to select the best treatment for each patient. In the process, physicians should be aware of the increased complexity of this therapy and the need for a clinical gerologist in order to evaluate and manage the patient and to manage the medications." - Anonymous Online Contributor